Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
• Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
• First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy.
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results/
• Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
• First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy.
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results/
